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Outcomes of Trans-Carotid TAVR in a High-volume Center
Vishesh Kumar, MD,1,2 Brandon M. Jones, MD,1,2 Ethan C. Korngold, MD,1,2 Robert W. Hodson, MD,1,2 Shih Ting Chiu Ph.D., 1 and Eric B. Kirker, MD 1,2
Background
• Transcatheter aortic valve replacement (TAVR) has become 
standard of care for most patients with severe symptomatic 
aortic stenosis. Transfemoral access (TF) is preferred 
access and remain gold standard.
• Registry based data has shown that in upto 20% of the 
patients TF access is not feasible due to many patients 
related factors.
• Given exponential growth in the volume of TAVR 
procedures, there is an unmet need to establish other 
optimal alternative access when TF access is not feasible.
• We look to compare short-term outcomes by access route at 
a single center, high-volume, trans-carotid (TC), TAVR 
program.
Methods
• All patients undergoing TAVR at Providence Heart Institute 
between 9/2012 and 9/2018 were included in the study.
• Baseline demographics and 30-day outcomes were obtained 
from data that our institution submitted in compliance with 
TVT reporting and were also reviewed and confirmed.
• Logistic model or ANOVA were considered  for categorical 
and continuous responses and simulation-based 
adjustments were applied for pairwise comparison. All 
significant tests were performed independently across 
factors (Univariate tests without covariates).
Conclusions
• TC TAVR can be safely performed with similar 30-day 
mortality outcomes as TF access.
• Mortality significantly increased with other accesses 
compared with TF access.
1 Center for Cardiovascular Analytics, Research and Data Science,  2 Providence Heart Institute, Providence St. Joseph Health, Portland, OR 
Results
• Total of 1153 TAVR were performed at Providence Heart 
Institute between 9/2012 and 9/2018. 
• 976 (85%) were performed via TF access, 105 (9%) via TC 
access and 72 (6%) via other access group (transapical, 
axillary or transaortic).
• TF group had significantly lower STS score, peripheral 
vascular disease and COPD, compared to TC and other 
access.
• Other access had significantly higher days in ICU and overall 
hospital compared to TF and TC. Even though TC access 
had higher ICU length of stay, overall hospital stay was 
similar to TF.
• 30-day mortality was higher in other access group (13.9%) 
compared to TF 2.6% (P <0.0001) and TC (P <0.055). 
• There was no statistically significant difference in 30-day 
stroke rates among all accesses; TF 2.6%, TC 1.9% and 
others 4.2%.










81(10) 80(  8) 82(  8)
Sex (Female) N(%) 477(49) 54(51) 40(56)
BMI Mean(SD)
29.0(  8) 27.8(  7) 27.3(  5)
Race (White) N(%) 948(97) 101(96) 70(97)
Diabetes N(%) 340(35) 47(45) 31(43)
Insulin dependence N(%) 123(13) 20(19) 13(18)
Moderate to severe chronic lung 
disease N(%) 139(14) 31(30) 21(30)
Hypertension N(%) 858(88) 96(91) 64(89)
Immunosuppression N(%) 88(  9) 9(  9) 10(14)
Creatinine level Mean(SD)
1.3(1.0) 1.4(1.4) 1.3(0.9)
Dialysis N(%) 37(  4) 5(  5) 2(  3)
Cerebrovascular disease N(%) 111(11) 18(17) 23(32)
Peripheral vascular disease N(%) 235(24) 92(88) 52(72)
Previous stroke N(%) 114(12) 14(13) 7(10)
Previous CABG N(%) 188(19) 29(28) 27(38)
Previous valve procedure N(%) 116(12) 13(12) 7(10)
NYHA class 3 or  4 N(%) 580(59) 62(59) 37(51)
Ejection fraction Mean(SD)
57(15) 57(14) 59(13)















(SD) 40 (15) 36 (13) 39 (11)
Fluoroscopy time Median (IQ) 9.3 (6.9) 8.7 (4.8) 10.8 (7.6)
PRBC use N(%) 54 (6) 5 (5) 11 (15)
PRBC units transfused Mean (SD) 3.4 (2.5) 4.2 (1.8) 3.7 (3.6)
Procedure Time Median (IQ) 62 (28) 67 (20) 100 (39)
ICU (Hours) Median (IQ) 0 (26) 26 (8) 46 (47)
Postop LOS Median (IQ) 2 (2) 3 (1) 6 (6)
Preoperative & Procedure Outcomes
TC TAVR can be safely performed with similar 30-day stroke and mortality outcomes as TF access
TF = Trans-femoral, TC = Trans-carotid, Others = (Trans-apical, aortic or axillary) 
Values colored in red: P < 0.05 when compared to TF access
Cells colored in blue: P < 0.05 in comparison between TC and others
Values colored in red: P < 0.05 when compared to TF access
Cells colored in blue: P < 0.05 in comparison between TC and others
